JMIA vs TSLA

Jumia Technologies exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. While the company maintains strong top-line revenue growth of 34.4%, this is offset by a devastating ROE of -109.87% and a Price-to-Book ratio of 32.26, which suggests extreme overvaluation relative to its equity. The lack of a Graham Number or Intrinsic Value reflects the absence of positive earnings, making the stock a highly speculative play. Despite bullish analyst targets, the deterministic data points to a high-risk profile with significant capital erosion over the long term.

Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.